A phase IB study of the pharmacokinetics of gemcitabine and pemetrexed, when administered in rapid sequence to patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 55, Issue 6, 2005, Pages 522-530

  Dy, Grace K ^a   Suri, Ajit ^b   Reid, Joel M ^a   Sloan, Jeff A ^a   Pitot, Henry C ^a   Alberts, Steven R ^a   Goldberg, Richard M ^a,c   Atherton, Pamela J ^a   Hanson, Lorelei J ^a   Burch, Patrick A ^a   Rubin, Joseph ^a   Erlichman, Charles ^a   Adjei, Alex A ^a  

^a MAYO CLINIC   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Combination chemotherapy; Gemcitabine; Pemetrexed; Pharmacokinetics; Schedule

Indexed keywords

AMINOTRANSFERASE; DEXAMETHASONE; GEMCITABINE; ONDANSETRON; PEMETREXED;

ADULT; ADVANCED CANCER; ALOPECIA; ANEMIA; ANOREXIA; ANUS CARCINOMA; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; CARCINOID; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; EPISTAXIS; ESOPHAGUS CARCINOMA; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; HYPONATREMIA; LEIOMYOSARCOMA; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MALE; MESOTHELIOMA; MYALGIA; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SIDE EFFECT; SOLID TUMOR; SORE THROAT; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUTAMATES; GUANINE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA;

EID: 21044446646     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-004-0950-7     Document Type: Article

References (23)

1. Plunkett W, Huang P, Xu YZ, et al (1995) Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 22 [Suppl 11]:3-10
2. Shih C, Chen VJ, Gossett LS, et al (1997) LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 57:1116-1123
3. Rusthoven J, Eisenhauer E, Butts C, et al (1999) Multitargeted antifolate, LY231514, as first-line chemotherapy for patients with advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 17:1194-1199
4. Clarke S, Millward M, Findlay M, et al (1998) Activity of the multi-targeted antifolate MTA (LY231514) in advanced non-small cell lung cancer (NSCLC). Ann Oncol 9 [Suppl 4]:86
5. John W, Picus J, Blanke C, et al (2000) Multitargeted antifolate (pemetrexed disodium, LY231514) activity in patients with advanced colorectal cancer: results from a phase II study. Cancer 88:1807-1813
6. Cripps C, Burnell M, Jolivet J, et al (1999) Phase II study of first-line LY231514 (multitargeted antifolate) in patients with locally advanced or metastatic colorectal cancer: an NCIC Clinical Trials Group study. Ann Oncol 10:1175-1179
7. Miles DW, Smith IE, Coleman RE, et al (2001) A phase II study of pemetrexed disodium (LY231514) in patients with locally recurrent or metastatic breast cancer. Eur J Cancer 37:1366-1371
8. Miller KD, Loehrer PJ, Picus J, et al (2000) Phase II study of the multi-targeted antifolate LY231514 (ALIMTA), MTA, pemetrexed disodium) in patients with advanced pancreatic cancer. Ann Oncol 11:101-103
9. Celio L, Bajetta E, Toffolatti L, et al (2000) Phase II trial of pemetrexed disodium administered every 21 days in patients (pts) with gastric cancer: efficacy and toxicity without and with folic acid. Ann Oncol 11 [Suppl 4]:65
10. Pivot X, Raymond E, Laguerre B, et al (2001) Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck. Br J Cancer 85:649-655
11. Paz-Ares L, Tabernero J, Moyano A, et al (1998) Significant activity of the multi-targeted antifolate MTA (LY231514) in advanced transitional cell carcinoma (TCC) of the bladder: results of a phase II trial. Ann Oncol 9 [Suppl 4]:61
12. Goedhals L, van Wijk AL (1998) MTA (LY231514) in advanced carcinoma of the cervix. Ann Oncol 9 [Suppl 2]:761
13. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21(14):2636-2644
14. Adjei AA, Erlichman C, Sloan JA, et al (2000) Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors. J Clin Oncol 18:1748-1757
15. Tonkinson JL, Worzalla JF, Teng CH, et al (1999) Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma. Cancer Res 59:3671-3676
16. Teicher BA, Chen V, Shih C, et al (2000) Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts. Clin Cancer Res 6:1016-1023
17. Chaudhary AK, Schannen V, Knadler MP, et al (1999) Analysis of LY231514 by LC/MS/MS. In: The 47th ASMS Conference on Mass Spectrometry and Allied Topics, Dallas, TX
18. Benet LZ, Galeazzi RL (1979) Noncompartmental determination of the steady-state volume of distribution. J Pharm Sci 68(8):1071-1074
19. Rowland M, Tozer T (1995) Clinical pharmacokinetics. Concepts and applications, 3rd edn. Lippincott Williams & Wilkins, Media, Pennsylvania, p 318
20. Adjei AA (2003) Pemetrexed (Alimta): a novel multitargeted antifolate agent. Expert Rev Anticancer Ther 3(2):145-156
21. Tesei A, Ricotti L, De Paola F, et al (2002) In vitro schedule-dependent interactions between the multitargeted antifolate LY231514 and gemcitabine in human colon adenocarcinoma cell lines. Clin Cancer Res 8:233-239
22. Tonkinson JL, Marder P, Andis SL, et al (1997) Cell cycle effects of antifolate antimetabolites: implications for cytotoxicity and cytostasis. Cancer Chemother Pharmacol 39:521-531
23. Niyikiza C, Baker SD, Seitz DE, et al (2002) Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 1:545-552